The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower ...

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...

Two bills heard in a state Senate committee are designed to lower prices, provide fair competition for independent pharmacies ...

RFK Jr.'s call to ban TV advertisements for prescription drugs reignited support for a bipartisan bill that would mandate the ...

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and ...

Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...

Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.